STOCK TITAN

BeiGene Ltd - BGNE STOCK NEWS

Welcome to our dedicated news page for BeiGene (Ticker: BGNE), a resource for investors and traders seeking the latest updates and insights on BeiGene.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BeiGene's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BeiGene's position in the market.

Rhea-AI Summary
BeiGene receives positive opinion from CHMP for tislelizumab as monotherapy for esophageal squamous cell carcinoma after prior chemotherapy. The Phase 3 study showed a statistically significant and clinically meaningful survival benefit for tislelizumab compared to chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
none
-
Rhea-AI Summary
BeiGene's sNDA for BRUKINSA in combination with obinutuzumab for the treatment of relapsed or refractory follicular lymphoma has been accepted for review by the FDA. The target action date is set for the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
partnership
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.4%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.4%
Tags
none
Rhea-AI Summary
BeiGene presents new data from its blood cancer portfolio at the 2023 EHA Hybrid Congress. The results show the potential of BRUKINSA in various B-cell malignancies. Safety analyses demonstrate that BRUKINSA is generally well-tolerated. Promising early-stage pipeline products, including BGB-16673 and BGB-11417, also show potential in treating blood cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.03%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
conferences
BeiGene Ltd

Nasdaq:BGNE

BGNE Rankings

BGNE Stock Data

14.97B
762.01M
0.03%
48.09%
1.65%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
China (Mainland)
Changping District

About BGNE

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.